Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Approximately 340 therapy-naïve MS patients with relapsing-remitting form of the disease will be randomized to receive Avonex alone or Avonex plus methylprednisolone (MP). Patients will receive MP as 500 mg po for 3 days every month or matching placebo. The patients are followed on a 3-monthly basis for 4 years with disability as the primary parameter of efficacy over that time.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent
Relapsing remitting MS according to Poser criteria or McDonell criteria and naïve to therapy
Disability EDSS score of 4.0 or less at baseline
Clinical activity as defined by at least one relapse in the last year
